Halozyme Therapeutics (HALO) : 4 brokerage houses believe that Halozyme Therapeutics (HALO) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 1.6.
Halozyme Therapeutics (HALO) : The highest level Halozyme Therapeutics (HALO) is projected to reach is $16 for the short term and the lowest estimate is at $7. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $12.58 and the possibility the share price can swing is $5.08.
For the current week, the company shares have a recommendation consensus of Buy. Halozyme Therapeutics (NASDAQ:HALO): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.05 and $9.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.16, notching a gain of 1.09% for the day. The total traded volume was 1,267,806 . The stock had closed at $10.05 on the previous day.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CFO of Halozyme Therapeutics Inc, Stelzer Laurie, had purchased 10,000 shares in a transaction dated on August 20, 2015. The transaction was executed at $17.24 per share with total amount equaling $172,400.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.